BIVI 4-DAY DEADLINE ALERT: Hagens Berman Encourages BioVie (BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline
March 15, 2024 12:52 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 –...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations
January 17, 2024 15:14 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
January 11, 2024 10:25 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
January 05, 2024 14:08 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
December 25, 2023 11:15 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 25, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
December 21, 2023 10:25 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
December 18, 2023 14:32 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
December 13, 2023 16:36 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
December 04, 2023 15:23 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
November 30, 2023 14:21 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit:...